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Abstract
Tight glucose control during labor and delivery is recommended for pregnant women with type 1 diabetes. This
can be challenging to achieve using the current treatment modalities. The automated nature of closed loop and
its ability to adapt to real-time glucose levels make it well suited for use during labor, delivery, and the
immediate postpartum period. We report observational data of participants from two randomized crossover
trials who chose to continue using closed loop during labor, delivery, and postpartum. Labor was defined as the
24 h before delivery and postpartum as the 48 h after delivery. The glucose target range during pregnancy was
3.5–7.8mmol/L (63–140mg/dL) and 3.9–10mmol/L (70–180mg/dL) after delivery. Twenty-seven (84.4%) of
the potential 32 trial participants used closed loop through labor, delivery, and postpartum. Use of closed loop
was associated with 82.0% (interquartile range [IQR] 49.3, 93.0) time-in-target range during labor and delivery
and a mean glucose of 6.9– 1.4mmol/L (124– 25mg/dL). Closed loop performed well throughout vaginal,
elective, and emergency cesarean section deliveries. Postpartum, women spent 83.3% (IQR 75.2, 94.6) time-in-
target range (3.9–10.0mmol/L [70–180mg/dL]), with a mean glucose of 7.2– 1.4mmol/L (130– 25mg/dL).
There was no difference in maternal glucose concentration between mothers of infants with and without
neonatal hypoglycemia (6.9– 1.6mmol/L and 6.8– 1.1mmol/L [124– 29mg/dL and 122– 20mg/dL] respec-
tively; P = 0.84). Automated closed-loop insulin delivery is feasible during hospital admissions for labor,
delivery, and postpartum. Larger scale studies are needed to evaluate its efficacy compared with current clinical
approaches as well as understand how women and healthcare providers will adopt this technology.
Keywords: Diabetes, Pregnancy, Closed loop, Insulin, Labor and delivery.
Background
Achieving optimal glycemic control throughout preg-nancy remains exceptionally demanding for women
with type 1 diabetes (T1D).1 Peripartum maternal hypergly-
cemia is frequently, but inconsistently, associated with a
higher risk of neonatal hypoglycemia.2 Thus, tight glucose
control during labor and delivery is generally recommended.3–5
The physiological stresses and dramatic changes in insulin
doses during labor and delivery, supervised by obstetric
ward staff with limited diabetes expertise, represent a un-
ique challenge.
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The changes in cortisol, increased glucose utilization by
uterine and skeletalmuscles, and the dramatic decrease in insulin
resistance immediately after deliverymake tight control difficult
to achieve.6 Even with the recommended hourly capillary glu-
cose monitoring, hypo- and hyperglycemic excursions are
common and frequent insulin dose adjustments are required.4,7
Variable rate intravenous insulin infusion (VRIII) and
continuous subcutaneous insulin infusion (CSII) are the most
commonly used modes of insulin delivery during labor and
delivery. Women on multiple daily injections (MDI) are
generally treated with VRIII. Those on CSII are often
transitioned to VRIII, however, if women are comfortable
self-managing their CSII and can maintain the target glu-
cose concentration, insulin pump therapy can be safely
continued.4,5,7 Self-management using CSII is less invasive
and may provide better glycemic control than VRIII during
this period.7
Furthermore, some women report feeling vulnerable when
the ability to control their own glucose is taken away from
them and is instead ‘‘in the hands’’ of less experienced ob-
stetric ward staff.8 For women who continue managing their
own insulin delivery, the burden of frequent monitoring and
insulin dose adjustments can be stressful.9
A hybrid closed-loop system uses a continuous glucose
monitor (CGM), CSII, and computer algorithm to provide
automated glucose-responsive insulin delivery. In preg-
nancy, it has been shown to improve overnight time in target
and safely maintain effective glucose control with less hy-
poglycemia compared with sensor-augmented pump (SAP)
therapy.10,11 Its automated nature with minimal obstetric staff
and user input makes it well suited for use during labor,
delivery, and the immediate postpartum period.
Two randomized crossover trials of home closed loop in
pregnancy have been performed. The first examined the ef-
ficacy of overnight closed loop and demonstrated better
glucose control overnight when compared with SAP thera-
py.10 The second trial examined day and night use of closed
loop in pregnancy and found comparable glucose control
measured by time in target with less hypoglycemia.11 We
report on data collected from these randomized crossover
trials examining in pregnancy.10,11
The aim of this study is to evaluate the feasibility and
safety of closed loop for maintaining glucose control in
women with T1D during labor, delivery, and the immediate
postpartum period.
Methods
Participants
Both trials recruited pregnant women 18 to 45 years of
age with T1D duration of at least 12 months and HbA1c of
6.5%–10% (48–86mmol/mol). Women were randomized to
4 weeks of closed loop and 4 weeks of SAP therapy, separated
by a 1–2-week washout period. After completing both arms,
women could choose to continue using SAP, closed loop,
or their preferred CGM/CSII/MDI combination. Women who
used closed loop for labor and delivery could continue it until
their discharge from hospital during the overnight study10 or
for up to 6 weeks postpartum in the day-and-night study.11
The trial protocols were approved by Regional Ethics
Committees. As both protocols allowed for use of data
throughout pregnancy, no separate consent was required.
Study design
This was an observational study of all women included in
the trials described who chose to use closed loop during labor,
delivery, and the immediate postpartum period.
‘‘Labor’’ was defined as the 24 h prior to delivery and ‘‘the
immediate postpartum period’’ as the 48 h after delivery.
Glucose control was measured by CGM (FreeStyle Navigator
2; Abbott Diabetes Care, Alameda, CA), insulin delivery was
through a DANA-R pump (Diabecare, Sooil, Seoul, South
Korea) and the closed-loop systems used were the Florence
D2W and Florence D2A (both University of Cambridge,
Cambridge, UK). The control algorithm was on a tablet PC
for the former and on an Android phone for the latter.
The glucose target range during pregnancy was 3.5–
7.8mmol/L (63–140mg/dL). These targets were changed to
3.9–10mmol/L (70–180mg/dL) immediately after deliv-
ery. There were no cues or changes in programming to an-
nounce the onset of labor and/or delivery. Women were
administered preprandial and any additional correction bo-
luses through their insulin pump or the Android mobile
phone if they were using the Florence D2A system.
Women were advised to change their insulin pump settings
and carbohydrate ratios as soon as possible after delivery,
with postnatal glucose targets of 6–10mmol/L (108–180mg/
dL). Participants were instructed not to bolus for their first
light meal and only to correct high glucose concentrations,
defined as ‡12mmol/L (216mg/dL).
Glucose control was assessed by mode of delivery (vaginal
delivery, emergency, or elective cesarean section). Maternal
hypoglycemic events during intrapartum and postpartum pe-
riods were defined as events lasting >20min with a CGM
glucose of <3.9mmol/L (70mg/dL) (level 1) and <3.5mmol/L
(63mg/dL) (level 2), respectively.
Statistical analyses
Glucose outcomes were calculated with GStat Version 2.2
software (University of Cambridge). Statistical analyses were
conducted using SPSS,R, and Stata version 14.1. The percentage
of time in target, time of hypoglycemia and time of hypergly-
cemia were summarized as mean (standard deviation [SD]) or
medians (interquartile range [IQR])where appropriate. Student’s
t-tests and Mann–Whitney–Wilcoxon tests were performed as
appropriate and presented with P-values and/or 95% confidence
intervals. A P-value of <0.05 was considered significant.
Results
Of the 32 women enrolled in the two closed-loop trials, 27
(84.4%) used closed loop during labor and delivery. They had
a mean age (SD) of 32.6 (4.6) years, diabetes duration of 21.9
(8.9) years, booking HbA1c 7.4 (0.9)% (57.2 [10.3] mmol/
mol), and body mass index of 28.3 (4.7) kg/m2. Five women
did not use closed loop during labor and delivery (n= 2 for
overnight trial and n = 3 for day-and-night trial). The reasons
for this included: maintaining tight glucose control on SAP
(n = 2), intermittent use (n= 1), delivery out of the country
(n = 1), and unknown (n = 1).
Anesthesia and infant delivery
The closed-loop system achieved a median time in target
of 84.3 (IQR 74.7, 88.8)%, 84.4 (IQR 48.5, 93.7)%, and 76.5
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(IQR 48.2, 93.0)% for vaginal delivery, emergency cesarean
section, and elective cesarean section, respectively (Table 1).
Participants also used closed loop under a variety of different
methods of anesthesia, including spinal, epidural, and general
anesthetic. Closed loop was used during both monopolar and
bipolar diathermy without complication. Monopolar and bi-
polar diathermy are tools commonly used in surgery, in-
cluding cesarean section, during which electric current is
used to cut tissues or achieve hemostasis. Additionally, one
participant underwent abdominal cystectomy under general
anesthetic following cesarean section under a spinal anes-
thetic. She maintained near normoglycemia throughout.
Obstetrical outcomes
The median gestational age at delivery was 37.0 weeks
(IQR 34.6, 37.7), with eight preterm deliveries (29.6%) and
15 (55.6%) large-for-gestational-age infants. There were 18
neonates (66.7%) with hypoglycemia defined as a glucose
concentration of <2.6mmol/L (47mg/dL); of these, 15 in-
fants (56%) were admitted to a neonatal intensive care unit
(NICU). A further three infants were admitted to NICU for
treatment of sepsis or jaundice but did not have neonatal
hypoglycemia. Six women had preeclampsia, three had
postpartum hemorrhages, and one had a severe urinary tract
infection requiring intravenous antibiotics.
Glycemic control outcomes
Women who used closed loop during labor and delivery
were in the target glucose range 82.0 (IQR 49.3, 93.0)% of
time, with a mean glucose concentration of 6.9 (1.4) mmol/L
(124 [25] mg/dL). Median sensor glucose variability mea-
sured by SD was 1.7 (1.2, 2.1) mmol/L (31 [22, 38] mg/dL).
The time spent above target was 16.0 (IQR 7.1, 46.7)%.
Hypoglycemia was uncommon; median (IQR) time was be-
low target 0 (0, 2.2)%. The median (IQR) number of hypo-
glycemic events was 0 (0, 1.0), although seven women
(26.9%) had at least 1 hypoglycemic event.
In the first 48 h postpartum, the mean glucose was 7.2 (1.4)
mmol/L (130 [25] mg/dL). During this period, women spent
83.3 (IQR 75.2, 94.6)% of the time-in-target range, with
minimal hyperglycemia median of (IQR) 9.1 (1.5, 20.6)%.
Median sensor glucose variability measured by SD was 2.4
(1.7, 2.8) mmol/L (43 [31, 50] mg/dL). Mild (level 1) hy-
poglycemia was slightly more common postpartum than
during labor and delivery; median (IQR) time <3.9mmol/L
(<70mg/dL) was 2.5 (0.9, 5.8)%. The median (IQR) number
of hypoglycemic events was 1.5 (1.0, 3.0). If a threshold
(level 2 hypoglycemia) of <3.5mmol/L (<63mg/dL) was
used, women did not have any hypoglycemic events in the
immediate postpartum period.
There were no incidents of severe hypoglycemia during
labor, delivery, or the immediate postpartum period, nor
were there serious device-related adverse events during this
time.
Neonatal hypoglycemia and maternal glucose
concentration in labor
There was no difference in mean glucose in mothers of
infants with neonatal hypoglycemia and those without
(mean [SD] maternal glucose of 6.9 [1.6] mmol/L and 6.8
[1.1] mmol/L [124 (29) and 122 (20) mg/dL], respec-
tively; P = 0.84). There was also no difference in the per-
centage of time in target (P = 0.88) (Fig. 1) or time above
target (P = 0.76).
Table 1. Glucose Control During Labor and Delivery by Mode of Delivery
Vaginal
delivery
n = 4
Emergency
cesarean
section n= 12
Elective
cesarean
section n= 11
Mean glucose, mmol/L (SD) 6.3 (0.2) 7.0 (1.5) 7.0 (1.6)
Mean glucose, mg/dL (SD) 113 (3.6) 126 (27) 126 (29)
Median time-in-target*, % (IQR) 84.3 (74.7, 88.8) 84.4 (48.5, 93.7) 76.5 (48.2, 93.0)
Median time below target, % (IQR) 0 (0, 3.4) 0.8 (0, 2.0) 0 (0, 2.2)
Median time above target, % (IQR) 15.7 (11.2, 22.0) 11.4 (6.3, 50.4) 16.5 (7.1, 51.8)
Median sensor glucose SD, mmol/L (IQR) 1.7 (1.4, 2.0) 1.5 (1.2, 2.2) 1.8 (1.1, 2.2)
Median sensor glucose SD, mg/dL (IQR) 31 (25, 36) 27 (22, 40) 32 (20, 40)
Median number of hypoglycemic events (IQR) 0 (0, 1.0) 0 (0, 1.0) 0 (0, 1.0)
Number of women with a hypoglycemic event (%) 1 (25.0) 3 (27.2) n = 11 3 (27.2)
*The glucose target range during labor and delivery was 3.5–7.8mmol/L (63–140mg/dL).
IQR, interquartile range; SD, standard deviation.
FIG. 1. Box plot of percentage of time in target during
labor and delivery for mothers of neonates with and without
neonatal hypoglycemia.
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Conclusions
In this cohort of women with a long duration of T1D,
closed loop performed well during labor and delivery.
Women spent over 80% time-in-target range with minimal
hypoglycemia. Closed loop maintained tight glycemic
control during vaginal deliveries and cesarean section under
both regional and general anesthesia. The system also
adapted quickly to the rapid change in insulin requirements
after delivery with women spending over 80% time-in-
target range in the immediate postpartum period.
The mean glucose achieved by women using closed loop
was comparable to that achieved by other cohorts examining
glycemic control in labor, allowing for differences in defi-
nitions and glycemic targets.7,12,13 Limited data are available
when evaluating time in target specifically. Drever et al. re-
ported time in target during labor and delivery using capillary
glucose monitoring in a retrospective observational study of
T1D women managed on VRIII or CSII.7 They found a
mean (SD) overall time in target of 47.7 (34.9)%. They had a
tight glucose control target range (4.0–6.0mmol/L [72–
108mg/dL]) with almost one third of women experiencing
at least one episode of hypoglycemia. They also found that
the mean maternal glucose concentration during delivery
was unrelated to poor neonatal outcomes, including neo-
natal hypoglycemia.
Closed-loop insulin delivery also offers potential benefits
beyond achieving optimal glycemic control. It may reduce
the need to transition from subcutaneous insulin therapy to
VRIII, which is expensive, invasive, limits mobility, and can
be distressing to women in labor. In addition to limited evi-
dence regarding its clinical efficacy, VRIII places a heavy
burden on the obstetric and delivery unit staff, who may have
limited diabetes management experience.
The rapid reduction in insulin requirements postpartum is
difficult to predict and highly variable,10 so closed loop might
be particularly useful in adjusting insulin doses in the post-
partum period. Closed loop has been demonstrated to be
feasible and effective in general and critical care inpatient
settings14,15 and offers the potential to improve inpatient
glycemic control while reducing the burden on staff, many
of whom are not specialized in diabetes management. In a
randomized controlled trial of 40 nonpregnant inpatients
with type 2 diabetes, a fully closed-loop system was asso-
ciated with a 22% improvement in the time-in-target range,
compared with the routine hospital protocol and was gen-
erally well-received by ward staff.14 These participants
were unfamiliar with CGM or insulin pumps before hospital
admission.
This demonstrates the potential for closed loop to be used
for isolated short-term periods when achieving optimal gly-
cemic control is challenging, including among diabetes
technology-naive participants. During pregnancy, these pe-
riods might include antenatal steroid administration, labor,
and delivery. It is important, however, to recognize that if this
approach were to be adopted, obstetric and delivery ward
staff would need to be trained in the basic principles of
closed-loop use and specialized support staff would need to
be available in case of technical difficulties.16
The main limitation of our study is the lack of a standard
VRIII or CSII control group with which to compare glucose
control. This was an observational study that included wo-
men who chose to use closed loop following the randomized
portion of two trials. This may have introduced bias in that
women included may be different from those who chose not
to use closed loop in labor and delivery. Unfortunately, we
did not have detailed information about postpartum insulin
dosing in the second trial, so these data could not be pre-
sented. We also lack data regarding the acceptability of the
system to hospital staff, although participants themselves
expressed generally high levels of satisfaction regarding
closed-loop experiences in semistructured interviews con-
ducted in related psychosocial studies.8 Thematic analysis of
these interviews revealed no negative comments regarding
participants’ experiences of closed loop. Participants’ posi-
tive comments included: ‘‘it just took all the worry away, to
be honest’’ (Participant 15, day-and-night trial); ‘‘there was
me saying to all these doctors, no I’d rather stay on that
[closed-loop], not the sliding scale.’’ (Participant 8, over-
night trial); and ‘‘I was using it even in my labor, my own
closed-loop, because it was working fine in making me more
relaxed. so I chose that [sic], rather than choosing the scale,
the insulin scale, because I felt more confident with the
closed-loop’’ (Participant 11, day-and-night trial).
Our study demonstrates the adaptability of closed loop
during labor, delivery, and the immediate postpartum period.
Further research is needed to compare the efficacy of closed
loop with current intrapartum sliding scale approaches and to
better understand the complex relationship between in-
trapartum glucose and neonatal hypoglycemia. As well, lar-
ger qualitative studies should be performed to learn more
about the perception of women with diabetes and their
healthcare providers regarding the acceptability of closed-
loop insulin delivery in this setting.
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